{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:02:33Z","timestamp":1761901353229,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.msard.2018.11.006","type":"journal-article","created":{"date-parts":[[2018,11,10]],"date-time":"2018-11-10T11:59:07Z","timestamp":1541851147000},"page":"276-280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Are there any clinical and electrocardiographic predictors of heart rate reduction in relapsing- remitting multiple sclerosis patients treated with fingolimod?"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5547-0235","authenticated-orcid":false,"given":"Duygu","family":"Kocyigit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammed U","family":"Yalcin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kadri M","family":"Gurses","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lale","family":"Tokgozoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana","family":"Karabudak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2018.11.006_bib0001","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.msard.2017.10.020","article-title":"Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis","volume":"19:","author":"Akbulak","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2018.11.006_bib0002","first-page":"915","article-title":"Electrocardiographic Tpeak-Tend interval and risk of cardiovascular morbidity and mortality: results from the Copenhagen ECG study","volume":"13:","author":"Bachmann","year":"2016","journal-title":"HeartRhythm"},{"key":"10.1016\/j.msard.2018.11.006_bib0003","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/archopht.121.7.944","article-title":"High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial","volume":"121:","author":"Beck","year":"2003","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.msard.2018.11.006_bib0004","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.pharmthera.2007.04.006","article-title":"Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology","volume":"115:","author":"Brinkmann","year":"2007","journal-title":"Pharmacol. Therap."},{"key":"10.1016\/j.msard.2018.11.006_bib0005","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1113\/jphysiol.1995.sp021084","article-title":"Activation of muscarinic K+ current in guinea-pig atrial myocytes by sphingosine-1-phosphate","volume":"489","author":"Bunemann","year":"1995","journal-title":"J. Physiol."},{"key":"10.1016\/j.msard.2018.11.006_bib0006","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13:","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2018.11.006_bib0007","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ahj.2014.06.028","article-title":"Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications","volume":"168:","author":"Camm","year":"2014","journal-title":"Am. Heart J."},{"key":"10.1016\/j.msard.2018.11.006_bib0008","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1161\/HYPERTENSIONAHA.117.09088","article-title":"S1PR1 (Sphingosine-1-Phosphate receptor 1) Signaling regulates blood flow and pressure","volume":"70:","author":"Cantalupo","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.msard.2018.11.006_bib0009","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1136\/jnnp-2014-310013","article-title":"Ventricular tachycardia on chronic fingolimod treatment for multiple sclerosis","volume":"86:","author":"Castillo-Trivino","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2018.11.006_bib0010","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33:","author":"Chun","year":"2010","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.msard.2018.11.006_bib0011","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362:","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2018.11.006_bib0012","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.msard.2014.05.005","article-title":"First-dose effects of fingolimod: Pooled safety data from three phase 3 studies","volume":"3:","author":"DiMarco","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2018.11.006_bib0013","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1053\/euhj.1998.1094","article-title":"The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens","volume":"19:","author":"Elming","year":"1998","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.msard.2018.11.006_bib0014","doi-asserted-by":"crossref","first-page":"e52985","DOI":"10.1371\/journal.pone.0052985","article-title":"The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P(1)) and hypertension (S1P(3)) in rat","volume":"7:","author":"Fryer","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2018.11.006_bib0015","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00415-013-7115-8","article-title":"Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study","volume":"261:","author":"Gold","year":"2014","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2018.11.006_bib0016","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.msard.2014.06.006","article-title":"First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis","volume":"3:","author":"Hughes","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2018.11.006_bib0017","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362:","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2018.11.006_bib0018","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s12603-014-0022-6","article-title":"Body mass index is related to autonomic nervous system activity as measured by heart rate variability\u2013a replication using short term measurements","volume":"18:","author":"Koenig","year":"2014","journal-title":"J. Nutr. Health Aging"},{"key":"10.1016\/j.msard.2018.11.006_bib0019","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12883-016-0789-7","article-title":"Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study","volume":"17:","author":"Limmroth","year":"2017","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2018.11.006_bib0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.msard.2016.04.002","article-title":"Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS)","volume":"8:","author":"Meissner","year":"2016","journal-title":"Mul. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2018.11.006_bib0021","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/ejcn.2009.35","article-title":"Body mass index is related to autonomic nervous system activity as measured by heart rate variability","volume":"63:","author":"Molfino","year":"2009","journal-title":"Eur. J. Clin. Nutr."},{"key":"10.1016\/j.msard.2018.11.006_bib0022","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/0735-1097(92)90376-X","article-title":"Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product","volume":"20:","author":"Molloy","year":"1992","journal-title":"J. Am. College Cardiol."},{"key":"10.1016\/j.msard.2018.11.006_bib0023","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1475-1313.2007.00501.x","article-title":"Recovery of vision and pupil responses in optic neuritis and multiple sclerosis","volume":"27:","author":"Moro","year":"2007","journal-title":"Ophthalmic Physiol. Opt."},{"key":"10.1016\/j.msard.2018.11.006_bib0024","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMct1101691","article-title":"Fingolimod for multiple sclerosis","volume":"366:","author":"Pelletier","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2018.11.006_bib0025","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ipej.2016.10.002","article-title":"P-wave dispersion: an update","volume":"16:","author":"Perez-Riera","year":"2016","journal-title":"Indian Pacing Electrophysiol. J."},{"key":"10.1016\/j.msard.2018.11.006_bib0026","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69:","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2018.11.006_bib0027","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1212\/WNL.0000000000000218","article-title":"Paroxysmal atrial fibrillation after initiation of fingolimod for multiple sclerosis treatment","volume":"82:","author":"Rolf","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.11.006_bib0028","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/sj.bjp.0707581","article-title":"Analysis of sphingosine 1-phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools","volume":"153:","author":"Salomone","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.msard.2018.11.006_bib0029","article-title":"Heart rate variability is differentially altered in multiple sclerosis: implications for acute, worsening and progressive disability","volume":"3:","author":"Studer","year":"2017","journal-title":"Mult. Sclerosis J.- Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2018.11.006_bib0030","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.ijcard.2016.07.134","article-title":"Tp-Te interval predicts heart rate reduction after fingolimod administration in patients with multiple sclerosis","volume":"221:","author":"Tocci","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.msard.2018.11.006_bib0031","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s13760-014-0297-8","article-title":"Ventricular arrhythmia in a male MS patient on fingolimod","volume":"115:","author":"van Pesch","year":"2015","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.msard.2018.11.006_bib0032","series-title":"37th Congress of IUPS","article-title":"Nerve conduction study and heart rate variability in obese persons","author":"Yadav","year":"2013"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818304917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818304917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:43:12Z","timestamp":1761900192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818304917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":32,"alternative-id":["S2211034818304917"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.11.006","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are there any clinical and electrocardiographic predictors of heart rate reduction in relapsing- remitting multiple sclerosis patients treated with fingolimod?","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}